Certain Balance Sheet Components (Tables)

6 Months Ended

Sep. 30, 2021

Other Liabilities Disclosure [Abstract]

Schedule of Cash and Cash Equivalents

The following represents a reconciliation of cash and cash equivalents in the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of September 30, 2021 and September 30, 2020, respectively, in the unaudited condensed consolidated statements of cash flows (in thousands):

	September 30,
	2021		2020
Cash and cash equivalents	$	518,163	$	94,210
Restricted cash	10,100		1,987
Total cash, cash equivalents and restricted cash	$	528,263	$	96,197

Schedule of Inventory

As of September 30, 2021 and March 31, 2021, inventories consisted of the following (in thousands):

	September 30, 2021		March 31, 2021
Raw materials	$	931	$	1,390
Work in process	1,960		773
Finished goods	3,250		448
Total inventories	$	6,141	$	2,611

Schedule of Accrued Liabilities

As of September 30, 2021 and March 31, 2021, accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2021		March 31, 2021
Accrued compensation-related expenses	$	17,111	$	20,571
Accrued sales discounts, rebates, and allowances	10,493		1,315
Accrued R&D expenses	7,354		8,544
Accrued commercial expenses	7,226		7,770
Accrued other expenses	3,525		5,315
Accrued professional fees	625		935
Deferred product revenue	—		162
Total accrued expenses and other current liabilities	$	46,334	$	44,612